...
首页> 外文期刊>JBMR plus. >Ibandronate Reduces the Surface Bone Resorption of Mandibular Bone Grafts: A Randomized Trial With Internal Controls
【24h】

Ibandronate Reduces the Surface Bone Resorption of Mandibular Bone Grafts: A Randomized Trial With Internal Controls

机译:IBANDRONATE降低下颌骨移植的表面骨吸收:随机试验,内部控制

获取原文
           

摘要

Autologous bone grafts are considered the gold standard for reconstruction of the edentulous alveolar ridges. However, this procedure is associated with unpredictable bone loss caused by physiological bone resorption. Bisphosphonates are antiresorptive drugs that act specifically on osteoclasts, thereby maintaining bone density, volume, and strength. It was hypothesized that the resorption of bone grafts treated with an ibandronate solution would be less advanced than bone grafts treated with saline. Ten patients who underwent bilateral sagittal split osteotomy were included in a randomized double‐blind trial with internal controls. Each patient received a bone graft treated with a solution of ibandronate on one side and a graft treated with saline (controls) contralaterally. Radiographs for the measurement of bone volume were obtained at 2?weeks and at 6 months after surgery. The primary endpoint was the difference in the change of bone volume between the control and the ibandronate bone grafts 6 months after surgery. All of the bone grafts healed without complications. One patient was excluded because of reoperation. In eight of the nine patients, the ibandronate bone grafts showed an increase in bone volume compared with baseline, with an average gain of 126?mm 3 (40% more than baseline) with a range of +27 to +218?mm 3 . Only one ibandronate‐treated graft had a decrease in bone volume (8%). In the controls, an average bone volume loss of ?146?mm 3 (58% of baseline) with a range of ?29 to ?301?mm 3 was seen. In the maxillofacial field, the reconstructions of atrophic alveolar ridges, especially in the esthetical zones, are challenging. These results show that bone grafts locally treated with ibandronate solution increases the remaining bone volume. This might lead to new possibilities for the maxillofacial surgeons in the preservation of bone graft volumes and for dental implant installations. ? 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.
机译:自体骨移植物被认为是重建芯片牙槽脊的金标准。然而,该程序与由生理骨吸收引起的不可预测的骨质损失有关。双膦酸盐是一种特异性在骨细胞体上的抗透镜药物,从而保持骨密度,体积和强度。假设用IBANDRONENT溶液处理的骨移植物的吸收将不如用盐水处理的骨移植物更进一步。患有双侧矢状分裂截骨术的十名患者包含在随机的双盲试验中,内部对照。每位患者接受用IBANDRONATE的溶液在一侧处理骨移植物,并对对侧用盐水(对照)处理的移植物。用于测量骨体积的射线照相在2℃,手术后6个月获得。初级终点是手术后6个月的对照和IBAND ronate骨移植物之间的骨体积变化的差异。所有骨移植物都没有并发症愈合。由于重组,一名患者被排除在外。在九个患者中的八个中,IBANDRONETENT骨移植物显示骨量增加与基线相比,平均增益为126Ωmm3(比基线40%超过40%),范围为+27至+218Ωmm3。只有一个IBandronate治疗的移植物的骨体积减少(8%)。在对照中,平均骨骼体积损失?146?mm 3(58%的基线),具有范围为29至αmm3。在颌面外场中,萎缩肺泡脊的重建,特别是在美学区,是具有挑战性的。这些结果表明,用IBANDRONENT溶液本地处理的骨移植增加了剩余的骨体积。这可能导致颌面外科医生在保存骨移植量和牙科植入物装置中的新可能性。还2021作者。 JBMR Plus由Wiley期刊LLC发布。代表美国骨骼和矿物学研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号